Craig Hofmeister, MD, MPH

Articles by Craig Hofmeister, MD, MPH

Optimizing Therapy in Frontline Multiple Myeloma Not Eligible for Transplant

ByC. Ola Landgren, MD, PhD,Craig Hofmeister, MD, MPH,Cristina Gasparetto, MD,Peter Voorhees, MD

December 24th 2021

Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.

Future Directions in Multiple Myeloma Care: Improvements and Unmet Needs

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 21st 2021

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Patient Case #2: A 77-Year-Old Man With Newly Diagnosed MM

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 21st 2021

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

Patient Case #1: A 75-Year-Old Woman With Newly Diagnosed MM

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 14th 2021

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

Treatment Options for First-Line Therapy in Transplant-Ineligible MM

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 14th 2021

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

Transplant-Ineligible MM: Treatment After Adequate Response to Therapy

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 7th 2021

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.